This afternoon we watched Moderna drop -5.3% to a price of $82.1 per share. The Large-Cap Biotechnology company is now trading -33.7% below its average target price of $123.84. Analysts have set target prices ranging from $58.0 to $310.0 per share for Moderna, and have given the stock an average rating of hold.
Moderna has an average level of shares sold short, at 7.7% of its total share float. The stock's short ratio (also called days to cover) is 8.24. The company's insiders own 9.52% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 72.7% of Moderna's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Baillie Gifford and Company | 11% | 43,449,041 | $3,567,166,199 |
| 2024-06-30 | Vanguard Group Inc | 10% | 39,562,796 | $3,248,105,491 |
| 2024-06-30 | Blackrock Inc. | 7% | 25,562,321 | $2,098,666,515 |
| 2024-06-30 | FMR, LLC | 6% | 21,161,285 | $1,737,341,466 |
| 2024-06-30 | State Street Corporation | 4% | 15,023,936 | $1,233,465,122 |
| 2024-06-30 | Theleme Partners LLP | 2% | 7,226,861 | $593,325,277 |
| 2024-06-30 | Geode Capital Management, LLC | 2% | 6,891,465 | $565,789,265 |
| 2024-06-30 | Morgan Stanley | 1% | 5,006,520 | $411,035,284 |
| 2024-06-30 | Flagship Pioneering Inc. | 1% | 4,632,149 | $380,299,425 |
| 2024-06-30 | Wellington Management Group, LLP | 1% | 4,318,571 | $354,554,672 |
